```
=> d his

     (FILE 'HOME' ENTERED AT 11:58:53 ON 18 MAY 2011)

     FILE 'REGISTRY' ENTERED AT 11:58:59 ON 18 MAY 2011
L1             STRUCTURE UPLOADED
L2              50 S L1
L3            1182 S 2436.13.8/RID
L4            1287 S L1 SSS FUL
L5             105 S L4 NOT L3
L6              23 S L5 AND 5-6-7/SZ
L7               5 S FLUOROBENZOYL AND L6
L8               2 S L6 AND SPIRO
L9               2 S L7 AND INDOLE
L10              4 S L8 OR L9
L11             82 S L5 NOT L6
L12             29 S L11 AND 5-5-7/SZ
L13             53 S L11 NOT L12
L14              8 S L13 AND 5-6-6-7/SZ
L15             45 S L13 NOT L14
L16              8 S L15 AND 5-5-6-7/SZ
L17             37 S L15 NOT L16
L18              3 S L17 AND INDOLE
L19             34 S L17 NOT L18
L20             38 S L10 OR L19
L21             36 S L20 AND CAPLUS/LC
L22              2 S L20 NOT L21

     FILE 'CAPLUS' ENTERED AT 12:08:56 ON 18 MAY 2011
L23             12 S L20
L24              8 S L23 NOT (2011/SO OR 2010/SO OR 2009/SO OR 2008/SO OR 2007/SO

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1:C,N
G2:O,S,N
G3:H,A,Cy


Structure attributes must be viewed using STN Express query preparation.


=> d ibib abs hitstr total
```

L24 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:1050008 CAPLUS
DOCUMENT NUMBER: 151:236777
TITLE: FXR agonists for treating vitamin D associated diseases
INVENTOR(S): Harnish, Douglas
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 53pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090215748	A1	20090827	US 2008-318039	20081219
PRIORITY APPLN. INFO.:			US 2007-8307P P	20071220

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Provided are certain methods of treating at least one condition that can be treated by elevating the vitamin D receptor (VDR) activity level in a patient with at least one farnesoid X receptor (FXR) agonist. Also provided are certain methods of modulating levels of Cytochrome P 450, family 27, subfamily B, polypeptide 1 (CYP27B1) and 1α,25-dihydroxyvitamin D3 in cells, certain methods of modulating VDR activity levels, certain methods of modulating levels of an extracellular matrix protein, renin angiotensin system (RAS) pathway, parathyroid hormone, serum creatinine, serum albumin, proteinuria, lipid metabolism, renal lipid deposition, mesangial expansion, glomerulosclerosis, kidney inflammation, blood pressure, bone resorption, and bone formation, certain methods of identifying FXR modulators, certain methods of diagnosing the risk that a patient will develop at least one condition that can be treated by elevating the VDR activity level, and certain methods of characterizing the levels of FXR activity in mammals.

IT 837429-85-3 837429-86-4 837429-88-6
837429-90-0, 6-(3,4-Difluoro-benzoyl)-4,4-dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-91-1
837429-92-2 837429-93-3 1088713-88-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(FXR agonists for treating vitamin D associated diseases)

RN 837429-85-3 CAPLUS
CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 837429-86-4 CAPLUS

CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-88-6 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX NAME)



RN 837429-90-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-91-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837429-92-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)



RN 837429-93-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl
ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:769550 CAPLUS
DOCUMENT NUMBER: 151:94051
TITLE: Farnesoid X receptor (FXR) agonists for the treatment of nonalcoholic fatty liver and cholesterol gallstone diseases
INVENTOR(S): Zhang, Songwen; Harnish, Douglas; Evans, Mark J.; Wang, Juan
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 61pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163474	A1	20090625	US 2008-253010	20081016
PRIORITY APPLN. INFO.:			US 2007-960925P P	20071019

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides methods for treating nonalcoholic fatty liver disease with farnesoid X receptor (FXR) agonists. The invention also provides methods for modulating levels of keratinocyte-derived chemokine (KC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), cytokeratin 18 (CK-18), matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-14 (MMP-14), tissue inhibitor of metalloproteinase 1 (TIMP-1), and Cytochrome P 450 2E1 (CYP2E1); methods for identifying FXR modulators; and methods for treating patients with existing cholesterol gallstone disease.

IT 837429-85-3 837429-86-4 837429-89-7
837429-90-0 837429-91-1 837429-92-2
837429-93-3 1088713-88-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(FXR agonist for treatment of nonalcoholic fatty liver and cholesterol gallstone disease)

RN 837429-85-3 CAPLUS
CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 837429-86-4 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-89-7 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester
(CA INDEX NAME)



RN 837429-90-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX
NAME)



RN 837429-91-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl
ester (CA INDEX NAME)



RN 837429-92-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)



RN 837429-93-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl
ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:647976 CAPLUS
DOCUMENT NUMBER: 151:1373
TITLE: 1,4,5,6-Tetrahydropyrrolo[2,3-d]azepines AND -imidazo[4,5-d]azepines as modulators of nuclear receptor activity
INVENTOR(S): Mehlmann, John Francis; Lundquist, Joseph Theodore, IV; Mahaney, Paige Erin; Crawley, Matthew Lantz; Kim, Callain Younghee
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 26pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090137554	A1	20090528	US 2008-255216	20081021
PRIORITY APPLN. INFO.:			US 2007-999990P P	20071022

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 151:1373; MARPAT 151:1373
GI



I

AB Disclosed are chemical entities including compds. of Formula (I and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF3, CF2H, S(O)nR8, and S(O)2N(R9)R10; n is 1, 2 or 3; Y is chosen from CR11 and N; Z is chosen from O and NH; R1 is chosen from optionally substituted alkyl, cycloalkyl, etc.; R2 is H or optionally substituted alkyl; R3 is chosen from -C(O)R12 and -C(O)N(R9)R10; R4, R5, R6 and R7 are independently chosen from H and optionally substituted alkyl; R8 is chosen from optionally substituted alkyl or cycloalkyl; R9 and R10 is chosen from H or optionally substituted aryl or heteroaryl, etc.; R11 is H or lower alkyl; R12 is H, optionally substituted aryl or heteroaryl, etc.); compns. comprising one or more such chemical entities; and methods of using one or more such chemical entities for modulating the activity of certain nuclear receptors (e.g., farnesoid X) or for the treatment or prevention of one or more symptoms of disease or disorder related to the activity of those receptors.

IT 1158716-04-1P 1158716-05-2P 1158716-06-3P
1158716-07-4P 1158716-08-5P 1158716-09-6P

1158716-10-9P 1158716-11-0P 1158716-12-1P
1158716-13-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetrahydropyrroloazepines and -imidazoazepines as modulators of farnesoid X receptors for disease treatment)

RN 1158716-04-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-05-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-6-(cyclohexylcarbonyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-06-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-6-(3-fluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-07-4 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-6-(4-fluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-,
1-methylethyl ester (CA INDEX NAME)



RN 1158716-08-5 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-6-(4-cyanobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl
ester (CA INDEX NAME)



RN 1158716-09-6 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
6-(3-chlorobenzoyl)-2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-,
1-methylethyl ester (CA INDEX NAME)



RN 1158716-10-9 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-6-(2-thienylcarbonyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-11-0 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-6-[3-(trifluoromethyl)benzoyl]-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-12-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-6-[(tetrahydro-2H-pyran-4-yl)carbonyl]-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-13-2 CAPLUS
CN Spiro[4H-pyran-4,4'(1'H)-pyrrolo[2,3-d]azepine]-8'-carboxylic acid, 2'-cyano-6'-(3,4-difluorobenzoyl)-2,3,5,5',6,6'-hexahydro-, 1-methylethyl ester (CA INDEX NAME)



IT 1155659-03-2P 1158716-22-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tetrahydropyrroloazepines and -imidazoazepines as modulators of farnesoid X receptors for disease treatment)
RN 1155659-03-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-22-3 CAPLUS
CN Spiro[4H-pyran-4,4'(1'H)-pyrrolo[2,3-d]azepine]-8'-carboxylic acid,

2'-cyano-2,3,5,5',6,6'-hexahydro-, 1-methylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:615712 CAPLUS
DOCUMENT NUMBER: 150:555909
TITLE: 1,4,5,6,7,8-Hexahydro-pyrrolo[2,3-d]azepines and -imidazo[4,5-d]azepines as modulators of nuclear receptor activity
INVENTOR(S): Mehlmann, John Francis; Lundquist, Joseph Theodore, IV; Mahaney, Paige Erin; Crawley, Matthew Lantz; Kim, Callain Younghee
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 25pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090131409	A1	20090521	US 2008-255232	20081021
PRIORITY APPLN. INFO.:			US 2007-11P P	20071022

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 150:555909; MARPAT 150:555909
GI



I

AB Disclosed are chemical entities including compds. of Formula (I and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF3, CF2H, S(O)nR8, and S(O)2N(R9)R10; n is 1, 2 or 3; Y is chosen from CR11 and N; Z is chosen from O and NH; R1 is chosen from optionally substituted alkyl, cycloalkyl, etc.; R2 is H or optionally substituted alkyl; R3 is chosen from -C(O)R12 and -C(O)N(R9)R10; R4, R5, R6 and R7 are independently chosen from H and optionally substituted alkyl; R8 is chosen from optionally substituted alkyl or cycloalkyl; R9 and R10 is chosen from H or optionally substituted aryl or heteroaryl, etc.; R11 is H or lower alkyl; R12 is H, optionally substituted aryl or heteroaryl, etc.); compns. comprising one or more such chemical entities; and methods of using one or more such chemical entities for modulating the activity of certain nuclear receptors (e.g., farnesoid X) or for the treatment or prevention of one or more symptoms of disease or disorder related to the activity of those receptors.
IT 1155659-03-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(hexahydro-pyrroloazepines and -imidazoazepines as modulators of farnesoid X receptor activity for treatment of disease)

RN 1155659-03-2 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2008:1457368 CAPLUS
DOCUMENT NUMBER: 150:16134
TITLE: Farnesoid X receptor (FXR) agonists for reducing lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) expression, and therapeutic use
INVENTOR(S): Harnish, Douglas; Zhang, Songwen
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 26pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080300235	A1	20081204	US 2008-130322	20080530
PRIORITY APPLN. INFO.:			US 2007-924822P P	20070601

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention provides methods for treating at least one disease state characterized by elevated expression of the lectin-like oxidized low-d. lipoprotein receptor 1 (LOX-1) in a patient with farnesoid X receptor (FXR) agonists. Also provided are methods for reducing expression of LOX-1 in a cell with FXR agonists.
IT 837429-85-3, 6-(4-Fluorobenzoyl)-3,6,7,8-tetrahydroimidazo(4,5-d)azepine-4-carboxylic acid ethyl ester 837429-86-4, 6-(3,4-Difluorobenzoyl)-5,6-dihydro-4H-thieno(2,3-d)azepine-8-carboxylic acid ethyl ester 837429-88-6, 3-(4-Fluorobenzoyl)1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-89-7, 3-(4-Fluorobenzoyl)-1,1-dimethyl-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-90-0 837429-91-1, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837429-92-2 837429-93-3 1088713-88-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(FXR agonists for reducing LOX-1 expression, and therapeutic use)
RN 837429-85-3 CAPLUS
CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)

RN 837429-86-4 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-88-6 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX NAME)



RN 837429-89-7 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-90-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-91-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837429-92-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 837429-93-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2008:1455334 CAPLUS
DOCUMENT NUMBER: 150:16058
TITLE: FXR agonists for the treatment of malignancies
INVENTOR(S): Hartman, Helen B.; Evans, Mark J.
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 25pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080299118	A1	20081204	US 2008-130221	20080530
PRIORITY APPLN. INFO.:			US 2007-924823P P	20070601

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Provided are certain methods of treating malignancies with farnesoid X receptor agonists. Also provided are certain methods of inducing RECK gene expression with farnesoid X receptor agonists and methods of reducing at least one feature of a cell with farnesoid X receptor agonists.

IT 837429-85-3, 6-(4-Fluorobenzoyl)-3,6,7,8-tetrahydroimidazo[4,5-D]azepine-4-carboxylic acid ethyl ester 837429-86-4, 6-(3,4-Difluorobenzoyl)-5,6-dihydro-4H-thieno[2,3-D]azepine-8-carboxylic acid ethyl ester 837429-88-6, 3-(4-Fluorobenzoyl)1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-89-7, 3-(4-Fluorobenzoyl)-1,1-dimethyl-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-90-0, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-91-1, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837429-92-2 837429-93-3 1088713-88-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesoid X receptor agonists for treatment of malignancies by inducing RECK gene expression)

RN 837429-85-3 CAPLUS
CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 837429-86-4 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-88-6 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX NAME)



RN 837429-89-7 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid,
3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-90-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid,
6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-91-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837429-92-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 837429-93-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2005:99333 CAPLUS
DOCUMENT NUMBER: 142:198048
TITLE: Azepine derivatives as pharmaceutical agents, specifically as farnesoid X receptor ligands, and their preparation, pharmaceutical compositions, and use in the treatment of lipid disorders, atherosclerosis, and diabetes
INVENTOR(S): Martin, Richard; Wang, Tie-Lin; Flatt, Brenton T.; Gu, Xiao-Hui
PATENT ASSIGNEE(S): X-Ceptor Therapeutics Inc., USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009387	A2	20050203	WO 2004-US23745	20040723
WO 2005009387	A3	20060302		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259009	A1	20050203	AU 2004-259009	20040723
CA 2532798	A1	20050203	CA 2004-2532798	20040723
EP 1648408	A1	20060426	EP 2004-779004	20040723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004012262	A	20060919	BR 2004-12262	20040723
CN 1852748	A	20061025	CN 2004-80027076	20040723
JP 2006528637	T	20061221	JP 2006-521272	20040723
JP 4679517	B2	20110427		
KR 2006052867	A	20060519	KR 2006-7001566	20060123
MX 2006000875	A	20060907	MX 2006-875	20060123
NO 2006000871	A	20060424	NO 2006-871	20060222
US 20070015746	A1	20070118	US 2006-565702	20060913
PRIORITY APPLN. INFO.:			US 2003-489854P P	20030723
			WO 2004-US23745 W	20040723

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 142:198048; MARPAT 142:198048
GI



I



II

AB Compds., compns., and methods are provided for modulating the activity of farnesoid X receptors, and for the treatment, prevention, or amelioration of one or more symptoms of diseases or disorders related to the activity of the receptors. In particular, compds. I are disclosed [wherein: X = O, S(O)0-2, NH or its alkyl, acylated, oxyacylated, or sulfonylated derivs.; Y = (un)substituted CH or N; Z = (un)substituted CH or N; or YZ bond is fused to a carbo- or heterocyclic ring, but not benzo or naphtho; R1, R2, R4-R7 = H, halo, (un)substituted alk(en/yn)yl, (hetero)aryl, numerous functional groups; R3 = H, (un)substituted alk(en/yn)yl, (hetero)aryl, numerous functional groups; R4R5 and/or R6R7 may form oxo, thioxo, (un)substituted imino or oxime or hydrazone, or an exocyclic double bond; or R4R5, R4R6, R4R7, R5R6, R5R7, and/or R6R7 may form ring(s); including isomer(s), solvates, polymorphs, prodrugs, and pharmaceutically acceptable salts]. Fifteen synthetic examples and several biol. examples are given. For instance, thiophene-3-acetonitrile was converted to invention compound II in four steps: (1) di-α-methylation using NaH and MeI in DMF; (2) reduction of the nitrile to a primary amine using LiAlH4; (3) cyclocondensation of the amine with Et bromopyruvate to form the azepine ring; and (4) N-acylation using 3,4-difluorobenzoyl chloride. II exhibited agonist activity at 100 nM or less, with > 100% efficacy (vs. CDCA), as measured in a co-transfection assay using full length human farnesoid X receptor.

IT 837429-84-2P, 3,6,7,8-Tetrahydroimidazo[4,5-d]azepine-4-carboxylic acid ethyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of azepine derivs. as farnesoid X receptor ligands for treatment of lipid disorders, atherosclerosis, and diabetes)

RN 837429-84-2 CAPLUS

CN Imidazo[4,5-d]azepine-4-carboxylic acid, 3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



IT 837429-85-3P, 6-(4-Fluorobenzoyl)-3,6,7,8-tetrahydroimidazo[4,5-d]azepine-4-carboxylic acid ethyl ester 837429-86-4P, 6-(3,4-Difluorobenzoyl)-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-88-6P, 3-(4-Fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-89-7P, 3-(4-Fluorobenzoyl)-1,1-dimethyl-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-90-0P, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-91-1P, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837429-92-2P, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester 837429-93-3P, 6-(3,4-Difluorobenzoyl)-1,4,4-trimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of azepine derivs. as farnesoid X receptor ligands for treatment of lipid disorders, atherosclerosis, and diabetes)

RN 837429-85-3 CAPLUS
CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 837429-86-4 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-88-6 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid, 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX NAME)



RN 837429-89-7 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid, 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-90-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-91-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl
ester (CA INDEX NAME)



RN 837429-92-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)



RN 837429-93-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid,
6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl
8-(1-methylethyl) ester (CA INDEX NAME)



IT 837429-95-5P, 5,6-Dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-96-6P, 4,4-Dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837430-02-1P, 4,4-Dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837430-03-2P, 4,4-Dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester 837430-05-4P, 1,4,4-Trimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of azepine derivs. as farnesoid X receptor ligands for treatment of lipid disorders, atherosclerosis, and diabetes)

RN 837429-95-5 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-96-6 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837430-02-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837430-03-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 837430-05-4 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1993:213072 CAPLUS
DOCUMENT NUMBER: 118:213072
ORIGINAL REFERENCE NO.: 118:36731a,36734a
TITLE: Preparation of imidazo[1,2-a](pyrrolo, thieno or furano)[3,2-d]azepines as allergy inhibitors
INVENTOR(S): Janssens, Frans Eduard; Diels, Gaston Stanislas Marcella; Leenaerts, Joseph Elisabeth; Cooymans, Ludwig Paul
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: Eur. Pat. Appl., 60 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 518434	A1	19921216	EP 1992-201665	19920609
R: PT				
IL 101851	A	19960514	IL 1992-101851	19920513
CN 1068116	A	19930120	CN 1992-104830	19920516
CN 1033587	C	19961218		
CA 2102889	A1	19921214	CA 1992-2102889	19920609
CA 2102889	C	20021126		
WO 9222553	A1	19921223	WO 1992-EP1331	19920609
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MW, NO, PL, RO, RU, SD, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
AU 9219011	A	19930112	AU 1992-19011	19920609
AU 652841	B2	19940908		
EP 588859	A1	19940330	EP 1992-911643	19920609
EP 588859	B1	20030813		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06507890	T	19940908	JP 1992-510734	19920609
JP 3182421	B2	20010703		
HU 70428	A2	19951030	HU 1993-3554	19920609
HU 221013	B1	20020729		
PL 170376	B1	19961231	PL 1992-301819	19920609
AT 247118	T	20030815	AT 1992-911643	19920609
ES 2204892	T3	20040501	ES 1992-911643	19920609
ZA 9204327	A	19931213	ZA 1992-4327	19920612
US 5461050	A	19951024	US 1993-150121	19931129
NO 9304493	A	19940104	NO 1993-4493	19931209
NO 300689	B1	19970707		
FI 104077	B1	19991115	FI 1993-5557	19931210

PRIORITY APPLN. INFO.: US 1991-714487 A 19910613
WO 1992-EP1331 A 19920609
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 118:213072
GI For diagram(s), see printed CA Issue.
AB Title compds. [I; R1 = H, alkyl, halo, ethenyl substituted with CO2H or alkoxycarbonyl, hydroxylalkyl, CHO, HO2C, hydroxycarbonylalkyl; R2 = H, alkyl, ethenyl or alkyl substituted with CO2H or alkoxy carbonyl, hydroxyalkyl, CHO, CO2H; R3 = H, alkyl, hydroxyalkyl, Ph, halo; L = H,

(substituted) alkyl, alkenyl, ZYQ1, ZNHCOQ2, ZQ3; Y = O, S, NH; Z = C1-4 alkylene; Q1, Q2 = (substituted) furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, oxodiazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazo[4,5-c]pyridin-2-yl; Q3 = Q1, (substituted) 4,5-dihydro-5-oxo-1H-tetrazolyl, 2-oxo-3-oxazolidinyl, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, etc.; X = O, S, NR5; R5 = H, alkyl, alkoxycarbonyl; dotted lines = optional double bonds] were prepared as broad spectrum antiallergics with excellent oral availability, lack of sedating properties, fast onset of action, and favorable duration of action (no data). Thus, [2-(1-methyl-1H-pyrrol-2-yl)ethyl] methanesulfonate was refluxed 3 daysa with imidazole and K2CO3 in THF to give 61.7% 1-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1H-imidazole. The latter and then Et6 1-methyl-4-piperidinecarboxylate were added to a -70° mixture of (MyCH)2NH and BuLi in THF. The mixture was stirred 1 h at -70° and 2 h at room temperature ti give 60% (1-methyl-4-piperidinyl)[1-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1H-imidazol-2-yl]methanone. This was stirred with MeSO3H at 80° to give 10.8% title compound II. Pharmaceutical I formulations are given.

IT 146800-88-6P, 4H-Thieno[2,3-d]azepin-5-amine
146800-89-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediates for imidazolazoloazepine inhibitor)

RN 146800-88-6 CAPLUS
CN 4H-Thieno[2,3-d]azepin-5-amine (CA INDEX NAME)



RN 146800-89-7 CAPLUS
CN 4H-Thieno[2,3-d]azepin-5-amine, N-(2,2-dimethoxyethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L22 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2011 ACS on STN
RN 50861-36-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 6H-Oxazolo[4,5-d]azepine (CA INDEX NAME)
MF C7 H6 N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L22 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2011 ACS on STN
RN 36726-22-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 6H-Thiazolo[4,5-d]azepine (CA INDEX NAME)
MF C7 H6 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT